What if the next breakthrough in liver disease comes from an algorithm rather than a lab bench? In this episode, Eliot sits down with Dr. Quin Wills, clinician, geneticist, and co-founder and CEO of Ochre Bio, an Oxford-based biotech using AI to tackle chronic liver disease.

In this episode we unpack what AI actually is (and isn't), how it's being used to discover new medicines, and why liver disease is one of the biggest health challenges most people have never heard about.

Along the way: why fatty liver used to be ignored by doctors, what large language models reveal about human intelligence, and whether AI could ever run a biotech on its own.

CHAPTERS: 

01:30 – Meet Quin Wills 

03:30 – Why genetics led him to AI 

04:32 – Liver disease: the myths 

06:40 – The obesity wave 

08:02 – A short history of AI 

11:40 – AI and the scientific method 

13:27 – How drugs get discovered 

16:21 – AI from lab to clinic 

19:29 – Better, cheaper, faster? 

22:00 – Why humans still matter 

24:46 – Biotech vs big pharma 

28:01 – Could AI replace scientists? 

30:15 – The chemistry comeback 

33:03 – The next frontier: causality 

36:15 – Failing forward in drug discovery 

37:47 – Treating disease in combination 

37:55 – What's next for Ochre Bio 

39:06 – Closing thoughts

FOLLOW QUIN: 

LinkedIn: https://www.linkedin.com/in/quinwills/

LEARN MORE ABOUT OCHRE BIO: 

LinkedIn: https://www.linkedin.com/company/ochre-bio/

This podcast was produced by Crisis What Crisis Productions. www.crisiswhatcrisis.com

With special thanks to Mintz: life sciences lawyers who help turn scientific breakthroughs into reality. https://www.mintz.com

Id. d’épisode : 1000764642441

GUID : 3e76309c-c329-4b35-b461-300ba3423c87

Date de publication : 30/4/2026 à 07:53:00